Expression and Function of Egf-Related Peptides and Their Receptors in Gynecological Cancer - From Basic Science to Therapy?

References

• Aaronson S. A. Growth factors and cancer. Science 1991; 254: 1146–1153
   PubMed Web of Science ®Google Scholar
• Campbell I. D., Boric P. Epidermal growth factor‐like modules. Curr. Opin. Structural Biol. 1993; 3: 385–392
   Google Scholar
• Groenen L. C., Nice E. C., Burgess A. W. Structure‐function relationships for the EGF/TGF‐α family of mitogens. Growth Factors 1994; 11: 235–257
   PubMed Web of Science ®Google Scholar
• Mason S., Gullick W. J. Type 1 growth factor receptors: an overview of recent developments. The Breast 1995; 4: 11–18
   Google Scholar
• Hynes N., Stern D. F. The biology of erb B‐2/neu/HER‐2 and its role in cancer. Biochim. Biophys. Acta 1994; 1198: 165–184
   PubMed Web of Science ®Google Scholar
• Riese D. J., III, Stern D. F. Specificity within the EGF family/Erb B receptor family signaling network. BioEssays 1998; 20: 41–48
   PubMed Web of Science ®Google Scholar
• Baulida J., Kraus M. H., Alimandi M., Fiore P. P., Carpenter G. All Erb B receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 1996; 271: 5251–5257
   PubMed Web of Science ®Google Scholar
• Alroy I., Yarden Y. The Erb B signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions. FEBS Lett. 1997; 410: 83–86
   PubMed Web of Science ®Google Scholar
• Beerli R. R., Hynes N. E. Epidermal growth factor‐related peptides activate distinct subsets of Erb B receptors and differ in their biological activities. J. Biol. Chem. 1996; 271: 6071–6076
   PubMed Web of Science ®Google Scholar
• Elenius K., Paul S., Allison G., Sun J., Klagsbrun M. Activation of HER4 by heparin‐binding EGF‐like growth factor stimulates chemotaxis but not proliferation. EMBO J. 1997; 16: 1268–1278
   PubMedGoogle Scholar
• Alimandi M., Wang L ‐M, Bottaro D., Lee C ‐C, Kuo A., Frankel M., Fedi P., Tang C., Lippman M., Pierce J. H. Epidermal growth factor and beta‐cellulin mediate signal transduction through co‐expressed Erb B2 and Erb B3 receptors. EMBO J. 1997; 16: 5608–5617
   PubMed Web of Science ®Google Scholar
• Bianco C., Kannan S., Santis M. De, Seno M., Tang C. K., Martinez‐Lacaci I., Kim N., Wallace‐Jones B., Lippman M. E., Ebert A. D., Wechselberger G., Salomon D. S. Cripto‐1 Indirectly Stimulates the Tyrosine Phosphorylation of erb BA through a Novel Receptor. J. Biol. Chem. 1999; 274: 8624–8629
   PubMedGoogle Scholar
• Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B. J., Yarden Y. A hierarchical network of interrecptor interaction determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 1996; 16: 5276–5287
   PubMed Web of Science ®Google Scholar
• Ling‐Mci W., Kuo A., Alimandi M., Veri M. C., Lee C‐C., Kapoor V., Ellmore N., Chen X‐H., Pierce J. H. Erb B2 expression increases the spectrum and potency of ligand‐mediated signal transduction through Erb B4. Proc. Natl. Acad. Sci. USA 1998; 95: 6809–6814
   Google Scholar
• Berchuck A., Rodriguez G., Kamel A., Soper J. T., Clark‐Pearson D. L., Bast R. C. Expression of epidermal growth factor receptor and Erb B‐2 in normal and neoplastic cervix, vulva and vagina. Obstet. Gynecol. 1990; 76: 381–387
   PubMed Web of Science ®Google Scholar
• Gullick W. J., Marsden J. J., Whittle N., Ward B., Bobrow L., Waterfield M. Expression of epidermal growth factor receptors in human cervical, ovarian and vulvar carcinomas. Cancer Res. 1986; 46: 285–292
   PubMed Web of Science ®Google Scholar
• Johnson G. A., Mannel R., Khalifa M., Walker J. L., Wren M., Min K. W., Benbrook D. M. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol. Oncol. 1997; 65: 425–429
   PubMed Web of Science ®Google Scholar
• Cannistra S. A., Niloff J. M. Cancer of the uterine cervix. N. Engl. J. Med. 1996; 334: 1030–1038
   PubMed Web of Science ®Google Scholar
• Rorke E. A. Antisense human papillomavirus (HPV) E6/E7 expression, reduced stability of epidermal growth factor, and diminished growth of HPV‐positive tumor cells. J. Natl. Cancer Inst. 1997; 89: 1243–1246
   Google Scholar
• Arends M. J., Buckley C. H., Wells M. Aetiology, pathogenesis, and pathology of cervical neoplasia. J. Clin. Pathol. 1998; 51: 96–103
   PubMed Web of Science ®Google Scholar
• Jones D. L., Munger K. Interactions of the human papillomavirus E7 protein with cell cycle regulators. Sem. Cancer Biol. 1996; 7: 327–337
   PubMed Web of Science ®Google Scholar
• Leechanachai P., Banks L., Moreau F., Matlashewski G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor‐mediated signal transduction to the nucleus. Oncogene 1992; 7: 19–25
   PubMed Web of Science ®Google Scholar
• Straight S. W., Hinkle P. M., Jewers R. J., McCance D. J. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 1993; 67: 4521–4532
   PubMed Web of Science ®Google Scholar
• Maruo T., Yamasaki M., Ladines‐Llave C. A., Mochizuki M. Immuno‐histochemical demonstration of elevated expression of epidermal growth factor receptor in the neoplastic changes of cervical squamous epithelium. Cancer 1992; 69: 1182–1187
   Google Scholar
• Tervahauta A., Syrjanen S., Syrjanen K. Epidermal growth factor receptor, c‐erb B‐2 proto‐oncogene and estrogen receptor expression in human papillomavirus lesions of the uterine cervix. Int. J. Gynecol. Pathol. 1994; 13: 234–240
   Google Scholar
• Von Knebel‐Doeberitz M., Gissmann L., Hausen H. Zur. Growth‐regulating functions of human papillomavirus early gene products in cervical cancer cells acting dominant over enhanced epidermal growth factor receptor expression. Cancer Res. 1990; 50: 3730–3736
   Google Scholar
• Woodworth C. D., McMullin E., Iglesias M., Plowman G. D. Interleukin la and tumor necrosis factor a stimulate autocrine amphiregulin expression and proliferation of human papillomavirus‐immortalized and carcinoma‐derived cervical epithelial cells. Proc. Natl. Acad. Sci. USA 1995; 92: 2840–2844
   PubMed Web of Science ®Google Scholar
• Hu G., Liu W., Mendelsohn J., Ellis L. M., Radinsky R., Andreeff M., Deisseroth A. B. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J. Natl. Cancer Inst. 1997; 89: 1271–1276
   PubMed Web of Science ®Google Scholar
• Von Knebel‐Doeberitz M., Rittmuller G., Hausen H. zur, Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6/E7 antisense RNA. Int. J. Cancer 1992; 51: 51831–51834
   Google Scholar
• Hamada K., Sakaue M., Alemany R., Zhang W. W., Horio Y., Roth J. A., Mitchell M. F. Adenovirus‐mediatcd transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol. Oncol. 1996; 63: 219–227
   PubMed Web of Science ®Google Scholar
• Rusch V., Mendelsohn J., Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev. 1996; 7: 133–141
   PubMedGoogle Scholar
• Brunton V. G., Carlin S., Workman P. Alterations in EGF‐dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor. Anticancer Drug Des. 1994; 9: 311–329
   Google Scholar
• Peto M., Tolle‐Ersu I., Krysch H. G., Klock G. Epidermal growth factor induction of human papillomavirus type 16 E6/E7 mRNA in tumor cells involves two AP‐1 binding sites in the viral enhancer. J. Gen. Virol. 1995; 76: 1945–1958
   PubMedGoogle Scholar
• Pfeiffer D., Spranger J., Al‐Deiri M., Kimmig R., Fisseler‐Eckhoff A., Scheidel P., Schatz H., Jensen A., Pfeiffer A. mRNA expression of ligands of the epidermal‐growth‐factor‐receptor in the uterus. Int. J. Cancer 1997; 72: 581–586
   Google Scholar
• Konishi I., Ishikawa Y., Wang S. ‐Y., Wang D. ‐P., Koshiyama M., Mandai M., Komatsu T., Yamamoto S., Mori T. Expression of transforming growth factor‐α in the normal cervix and in benign and malignant lesions of the uterine cervix. Brit. J. Obstet. Gynaecol. 1994; 101: 325–329
   Google Scholar
• Hembree J. R., Agarwal C., Eckert R. L. Epidermal growth factor suppresses insulin‐like growth factor binding protein 3 level in human papillomavirus type 16‐immortalized cervical epithelial cells and thereby potentiates the effects of insulin‐like growth factor‐1. Cancer Res. 1994; 54: 3160–3166
   PubMedGoogle Scholar
• Ueda M., Ueki M., Yamada T., Okamoto Y., Maeda T., Sugimoto O., Otsuki Y. Scatchard analysis of EGF receptor and effects of EGF on growth and TA‐4 production of newly established uterine cervical cancer cell line (OMC‐1). Hum. Cell 1989; 2: 401–410
   Google Scholar
• Steller M. A., Delgado C. H., Zou Z. Insulin‐like growth factor II mediates epidermal growth factor‐induced mitogenesis in cervical cancer cells. Proc. Natl. Acad. Sci. USA 1995; 92: 11970–11974
   PubMed Web of Science ®Google Scholar
• Steller M. A., Delgado C. H., Battels C. J., Woodworth C. D., Zou Z. Over‐expression of the insuline‐like growth factor‐1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res. 1996; 56: 1761–1765
   PubMed Web of Science ®Google Scholar
• Tonkin K. S., Berger M., Ormerod M. Epidermal growth factor status in four carcinoma of the cervix cell lines. Int. J. Gynecol. Cancer 1991; 1: 185–192
   Google Scholar
• Donato N. J., Yan D. H., Hung M. C., Rosenblum M. G. Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME‐180 squamous carcinoma cells. Cell Growth Differ. 1993; 4: 411–419
   Google Scholar
• Zheng Z. S., Goldsmith L. A. Modulation of epidermal growth factor receptors by retinoic acid in ME 180. Cancer Res. 1990; 50: 1201–1205
   Google Scholar
• Ueda M., Ueki M., Terai Y., Morimoto A., Fujii H., Yoshizawa K., Yanagihara T. Stimulatory effects of EGF and TGFα on invasive activity and 5‐deoxy‐5‐fluorouridine sensitivity in uterine cervical‐carcinoma SKG‐IIIB cells. Int. J. Cancer 1997; 72: 1027–1033
   Google Scholar
• Ueda M., Ueki M., Sugimoto O. Characterization of epidermal growth factor (EGF) receptor and biological effect of EGF on human uterine cervical adenocarcinoma cell line OMC‐4. Hum. Cell 1993; 6: 218–225
   Google Scholar
• Ozanne B., Richards C. S., Hendler F., Burns D., Gusterson B. Over‐expression of the EGF receptor is a hall mark of squamous cell carcinomas. J. Pathol. 1986; 149: 9–14
   PubMed Web of Science ®Google Scholar
• Pfeiffer D., Stellwag B., Pfeiffer A., Borlinghaus P., Meier W., Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol. Oncol. 1989; 33: 146–150
   PubMed Web of Science ®Google Scholar
• Kimmig R., Pfeiffer D., Landsmann H., Hepp H. Quantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2‐color flow cytometry: evidence for downregulation in cervical cancer. Int. J. Cancer 1997; 74: 365–373
   PubMed Web of Science ®Google Scholar
• Pfeiffer D., Kimmig R., Herrmann J., Ruge M., Fisseler‐Eckhoff A., Scheidel P., Jensen A., Schatz H., Pfeiffer A. Epidermal growth factor receptor correlates negatively with cell density in cervical squamous epithelium and is down‐regulated in cancers of the uterus. Int. J. Cancer 1998; 79: 49–55
   Google Scholar
• Goeppinger A., Wittmaack F. M., Wintzer H. O., Ikenberg H., Bauknecht T. Localization of human epidermal growth factor receptor in cervical intraepithelial neoplasias. J. Cancer Res. Clin. Oncol. 1989; 115: 259–263
   Google Scholar
• Hale R. J., Buckley C. H., Fox H., Williams J. Prognostic value of c‐erb B‐2 expression in uterine cervical carcinoma. J. Clin. Pathol. 1992; 45: 594–596
   Google Scholar
• Hale R. J., Buckley C. H., Gullick W. J., Fox H., Williams J., Wilcox F. L. Prognostic value of epidermal growth factor expression in cervical carcinoma. J. Clin. Pathol. 1993; 46: 149–153
   Google Scholar
• Hayashi Y., Hachisuga T., Iwasaka T., Fukada K., Okuma Y., Yokoyama M., Sugimori H. Expression of ras oncogene product and EGF receptor in cervical lymph node involvement. Gynecol. Oncol. 1991; 40: 147–151
   Google Scholar
• Kim J. W., Kim Y. T., Kim D. K., Song C. H., Lee J. W. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol. Oncol. 1996; 60: 283–287
   PubMed Web of Science ®Google Scholar
• Costa M. J., Walls J., Trelford J. D. c‐erb B‐2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease. Am. J. Clin. Pathol. 1995; 104: 634–642
   PubMed Web of Science ®Google Scholar
• Langlois N. E., Skinner L., Miller I. D. C‐erb B‐2 in cervical carcinoma. Am. J. Clin. Pathol. 1996; 106: 556–557
   Google Scholar
• Brumm C., Riviere A., Wilckens C., Loning T. Immunohistochemical investigation and northern blot analysis of c‐erb B‐2 expression in normal, pre‐malignant and malignant tissues of the corpus and cervix uteri. Virchows Arch. A Pathol. Anat. Histopathol. 1990; 417: 477–484
   Google Scholar
• Mitra A. B., Murty V. V., Pratap M., Sodhani P., Chaganti R. S. Erb B2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res. 1994; 54: 637–639
   PubMed Web of Science ®Google Scholar
• Kihana T., Tsuda H., Teshima S., Nomoto K., Tsugane S., Sonoda T., Matsuura S., Hirohashi S. Prognostic significance of the overexpression of c‐erb B‐2 protein in adenocarcinoma of uterine cervix. Cancer 1994; 73: 148–153
   PubMed Web of Science ®Google Scholar
• Ndubisi B., Sanz S., Lu L., Podczaski E., Benrubi G., Masood S. The prognostic value of HER‐2/neu oncogene in cervical cancer. Ann. Clin. Lab. Science 1997; 27: 396–401
   Google Scholar
• Lakshmi S., Nair M. Balaraman, Jayaprakash P. G., Rajalekshmy T. N., Nair M. Krishnan, Pillai M. Radhakrishna. c‐erb B‐2 oncoprotein and epidermal growth factor receptor in cervical lesions. Pathobiology 1997; 65: 163–168
   PubMed Web of Science ®Google Scholar
• Altavilla G., Castellan L., Wabersich J., Marchetti M., Onnis A. Prognostic significance of epidermal growth factor receptor (EGFR) and c‐erb B‐2 protein overexpression in adenocarcinoma of the uterine cervix. Eur. J. Gynaecol. Oncol. 1996; 17: 267–270
   Google Scholar
• Kristensen G. B., Holm R., Abeler V. M., Trope C. G. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c‐erb B‐2 in early cervical squamous cell carcinoma. Cancer 1996; 78: 433–440
   PubMed Web of Science ®Google Scholar
• Nakano T., Oka K., Ishikawa A., Morita S. Correlation of cervical carcinoma c‐erb B‐2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997; 79: 513–520
   PubMed Web of Science ®Google Scholar
• Horn Y. K., Young P., Wiesen J. F., Miettinen P. J., Derynck R., Werb Z., Cunha G. R. Uterine and vaginal organ growth requires epidermal growth factor receptor signaling from stroma. Endocrinology 1998; 139: 913–921
   Google Scholar
• Rasty G., Murray R., Lu L., Kubilis P., Benrubi G., Masood S. Expression of HER‐2/neu oncogene in normal, hyperplastic and malignant endometrium. Ann. Clin. Lab. Science 1998; 28: 138–143
   PubMedGoogle Scholar
• Pearl M. L., Talavera F., Gretz H. F., Roberts J. A., Menon K. M. Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC‐1‐A and KLE. Gynecol. Oncol. 1993; 49: 325–332
   Google Scholar
• Lelle R. J., Talavera F., Gretz H., Roberts J. A., Menon K. M. Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. Cancer 1993; 72: 519–525
   Google Scholar
• Watson H., Franks S., Bonney R. C. The epidermal growth factor receptor in the human endometrial adenocarcinoma cell line HEC‐1‐B. J. Steroid. Biochem. Mol. Biol. 1994; 51: 41–45
   Google Scholar
• Connor P., Talavera F., Kang J. S., Burke J., Roberts J., Menon K. M. Epidermal growth factor activates protein kinase C in the human endometrial cancer cell line HEC‐1A. Gynecol. Oncol. 1997; 67: 46–50
   Google Scholar
• Gretz H. F., Talavera F., Connor P., Pearl M., Lelle R. J., Roberts J. A., Menon K. M. Protein kinase C‐dependent and ‐ independent pathways mediate epidermal growth factor (EGF) effects in human endometrial adenocarcinoma cell line KLE. Gynecol. Oncol. 1994; 53: 228–233
   Google Scholar
• Krasilnikov M. A., Shatskaya V. A., Kuzmina Z. V., Barinov V. V., Letyagin V. P., Bassalyk L. S. Regulation of phospholipid turnover by steroid hormones in endometrial carcinoma and breast cancer cells. Acta Endocrinol. 1993; 128: 543–548
   Google Scholar
• Gershtein E. S., Shatskaya V. A., Kostyleva O. I., Ermilova V. D., Kushlinsky N. E., Krasilnikov M. A. Comparative analysis of the sensitivity of endometrial cancer cells to epidermal growth factor and steroid hormones. Cancer 1995; 76: 2524–2529
   Google Scholar
• Ueda M., Fujii H., Yoshizawa K., Abe F., Ueki M. Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG‐M cells in vitro. Jpn. J. Cancer Res. 1996; 87: 524–533
   PubMedGoogle Scholar
• Somkuti S. G., Yuan L., Fritz M. A., Lessey B. A. Epidermal growth factor and sex steroids dynamically regulate a marker of endometrial receptivity in Ishikawa cells. J. Clin. Endocrinol. Metab. 1997; 82: 2192–2197
   Google Scholar
• Burke J. J., Talavera F., Menon K. M. Regulation of PTP1D mRNA by peptide growth factors in the human endometrial cell line HEC‐1‐A. J. Soc. Gynecol. Investig. 1997; 4: 310–315
   Google Scholar
• Bolufer P., Lluch A., Molina R., Alberola V., Vazquez C., Padilla J., Garcia‐Conde J., Llopis F., Guillem V. Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM. Clin. Chim. Acta 1993; 215: 51–61
   Google Scholar
• Bauknecht T., Kohler M., Janz I., Pfleiderer A. The occurence of epidermal growth factor receptors and the characterization of EGF‐like factors in human ovarian, endometrial, cervical and breast cancer. EGF receptors and factors in gynecological carcinomas. J. Cancer Res. Clin. Oncol. 1989; 115: 193–199
   PubMedGoogle Scholar
• Niikura H., Sasano N., Kaga K., Sato S., Yajima A. Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. Hum. Pathol. 1996; 27: 282–289
   PubMed Web of Science ®Google Scholar
• Jasonni V. M., Amadori A., Santini D., Ceccarelli C., Naldi S., Flamigni C. Epidermal growth factor receptor (EGF‐R) and transforming growth factor alpha (TGFA) expression in different endometrial cancers. Anticancer Res. 1995; 15: 1327–1332
   Google Scholar
• Reinartz J. J., George E., Lindgren B. R., Niehans G. A. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c‐erb B‐2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum. Pathol. 1994; 25: 1075–1083
   PubMed Web of Science ®Google Scholar
• Nyholm H. C., Nielsen A. L., Ottesen B. Expression of epidermal growth factor receptors in human endometrial carcinomas. Int. J. Gynecol. Pathol. 1993; 12: 241–245
   Google Scholar
• Jasonni V. M., Santini D., Amadori A., Ceccarelli C., Naldi S. Epidermal growth factor receptor expression and endometrial cancer histotypes. Ann. N. Y. Acad. Sci. 1994; 734: 298–305
   Google Scholar
• Lamharzi N., Halmos G., Armatis P., Schally A. V. Expression of mRNA for luteinizing hormone‐releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int. J. Oncol. 1998; 12: 671–675
   PubMed Web of Science ®Google Scholar
• Emons G., Muller V., Ortmann O., Schultz K. D. Effects of LHRH‐analogues on mitogenic signal transduction in cancer cells. J. Steroid. Biochem. Mol. Biol. 1998; 65: 199–206
   PubMed Web of Science ®Google Scholar
• Reynolds R. K., Owens C. A., Roberts J. A. Cultured endometrial cancer cells exhibit autocrine growth factor stimulation that is not observed in cultured normal endometrial cells. Gynecol. Oncol. 1996; 60: 380–386
   Google Scholar
• Haining R. E., Cameron I. T., Papendorp C. van, Davenport A. P., Prentice A., Thomas E. J., Smith S. K. Epidermal growth factor in human endometrium: proliferative effects in culture and immunocytochemical localization in normal and endometriotic tissues. Hum. Reprod. 1991; 6: 1200–1205
   PubMed Web of Science ®Google Scholar
• Fujimoto J., Ichigo S., Hori M., Morishita S., Tamaya T. Estrogen induces c‐Ha‐ras expression via activation of tyrosine kinase in uterine endometrial fibroblasts and cancer cells. J. Steroid. Biochem. Mol. Biol. 1995; 55: 25–33
   Google Scholar
• Kato K., Ueoka Y., Kato K., Tamura T., Nishida J., Wake N. Oncogenic ras modulates epidermal growth factor responsiveness in endometrial carcinomas. Eur. J. Cancer 1998; 34: 737–744
   Google Scholar
• Sallot M., Ordener C., Lascombe I., Propper A., Adessi G. L., Jouvenot M. Differential EGF action on nuclear proto‐oncogenes in human endometrial carcinoma RL95–2 cells. Anticancer Res. 1996; 16: 401–406
   Google Scholar
• Anzai Y., Gong Y., Holinka C. F., Murphy L. J., Murphy L. C., Kuramoto H., Gurpide E. Effects of transforming growth factors and regulation of their mRNA levels in two human endometrial adenocarcinoma cell lines. J. Steroid. Biochem. Mol. Biol. 1992; 42: 449–455
   Google Scholar
• Yokoyama Y., Takahashi Y., Hashimoto M., Morishita S., Tamaya T. Immunhistochemical study of estradiol, epidermal growth factor, transforming growth factor alpha and epidermal growth factor receptor in endometrial neoplasia. Jpn. J. Clin. Oncol. 1996; 26: 411–416
   Google Scholar
• Murphy L. C., Dotzlaw H., Alkhalaf M., Coutts A., Miller T., Wong M. S., Gong Y., Murphy L. J. Mechanisms of growth inhibition by antiestrogens and progestins in human breast and endometrial cancer cells. J. Steroid. Biochem. Mol. Biol. 1992; 43: 117–121
   PubMed Web of Science ®Google Scholar
• Murphy L. J., Gong Y., Murphy L. C. Regulation of transforming growth factor gene expression in human endometrial adenocarcinoma cells. J. Steroid. Biochem. Mol. Biol. 1992; 41: 309–314
   Google Scholar
• Berchuck A., Rodriguez G., Kinney R. B., Soper J. T., Dodge R. K., Clarke‐Pearson D. L., Bast R. C., Jr. Overexpression of HER‐2/neu in endometrial cancer is associated with advanced stage disease. Am. J. Obstet. Gynecol. 1991; 164: 15–21
   PubMed Web of Science ®Google Scholar
• Ignar‐Trowbridge D. M., Nelson K. G., Bidwell M. C., Curtis S. W., Washburn T. F., McLachlan J. A., Korach K. S. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA 1992; 89: 4658–4662
   PubMed Web of Science ®Google Scholar
• Ignar‐Trowbridge D. M., Pimentel M., Teng C. T., Korach K. S., McLachlan J. A. Cross talk between peptide growth factor and estrogen receptor signaling systems. Envirom. Health Perspect. 1995; 103(suppl. 7)35–38
   PubMedGoogle Scholar
• Ignar‐Trowbridge D. M., Pimentel M., Parker M. G., McLachlan J. A., Korach K. S. Peptide growth factor cross‐talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinology 1996; 137: 1735–1744
   PubMed Web of Science ®Google Scholar
• Dam P. Van A., Lowe G., Watson J. V., James M., Chard T., Hudson C. N., Shepherd J. H. Multiparameter flow‐cytometric quantitation of epidermal growth factor receptor and c‐erb B‐2 oncoprotein in normal and neoplastic tissues of the female genital tract. Gynecol. Oncol. 1991; 42: 256–264
   Google Scholar
• Esteller M., Garcia A., Martinez I., Palones J. M., Cabero A., Reventos J. Detection of c‐erb S‐2/neu and fibroblast growth factor‐3/INT‐2 but not epidermal growth factor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer 1995; 75: 2139–2146
   PubMedGoogle Scholar
• Gong Y., Anzai Y., Murphy L. C., Ballejo G., Holinka C. F., Gurpide E., Murphy L. J. Transforming growth factor gene expression in human endometrial adenocarcinoma cells: regulation by progestins. Cancer Res. 1991; 51: 5476–5481
   PubMed Web of Science ®Google Scholar
• Xynos F. P., Klos D. J., Hamilton P. D., Schuette V., Fernandez‐Pol J. A. Expression of transforming growth factor alpha mRNA in benign and malignant tissues derived from gynecologic patients with various proliferative conditions. Anticancer Res. 1992; 12: 1115–1120
   PubMedGoogle Scholar
• Ayhan A., Tuncer Z. S., Ruacan S., Ayhan A., Yasui W., Tahara E. Abnormal expression of cripto and p53 protein in endometrial carcinoma and its precursor lesions. Eur. J. Gynaecol. Oncol. 1998; 19: 316–318
   Google Scholar
• Hetzel D. J., Wilson T. O., Keeney G. L., Roche P. C., Cha S. S., Podratz K. C. HER‐2/neu expression: a major prognostic factor in endometrial cancer. Gynecol. Oncol. 1992; 47: 179–185
   PubMed Web of Science ®Google Scholar
• Costa M. J., Walls J. Epidermal growth factor receptor and c‐erb B‐2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed mullerian tumors). Clinicopathologic study of 82 cases. Cancer 1995; 77: 533–542
   Google Scholar
• Kohlberger P., Loesch A., Koelbl H., Breitenecker G., Kainz C., Gitsch G. Prognostic value of immunohistochemically detected HER‐2/neu oncoprotein in endometrial cancer. Cancer Lett. 1996; 98: 151–155
   Google Scholar
• Seki A., Nakamura K., Kodama J., Miyagi Y., Yoshinouchi M., Kudo T. A lose correlation between c‐erbB‐2 gene amplification and local progression in endometrial adenocarcinoma. Eur. J. Gynaecol. Oncol. 1998; 19: 90–92
   Google Scholar
• Adachi K., Kurachi H., Homma H., Adachi H., Imai T., Sakata M., Higashiguchi O., Yamaguchi H., Morishge K., Sakoyama Y. Estrogen induces Epidermal growth factor (EGF) receptor and its ligands in human Fallopian tube: Involvement of EGF but not transforming growth factor‐α in estrogen‐induced tubal cell growth in vitro. Endocrinology 1995; 136: 2110–2119
   Google Scholar
• Adachi K., Kurachi H., Adachi H., Imai T., Sakata M., Homma H., Higashiguchi O., Yamamoto T., Miyake A. Menstrual cycle specific expression of epidermal growth factor receptors in human fallopian tube epithelium. J. Endocrinol. 1995; 147: 553–563
   Google Scholar
• Berchuck A., Kohler M. F., Bast R. C. Oncogenes in ovarian cancer. Hematol. Oncol. Clin. North Am. 1992; 6: 813–827
   Google Scholar
• Bauknecht T., Janz I., Kohler M., Pfleiderer A. Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors (EGF‐R) and EGF‐like faktors (EGF‐F). Med. Oncol. Tumor Pharmacother. 1989; 6: 121–127
   Google Scholar
• Bauknecht T., Angel P., Kohler M., Kommoss F., Birmelin G., Pfleiderer A., Wagner E. Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor‐alpha, myc, jun, and metallothionein in human ovarian carcinomas. Classification of malignant phenotypes. Cancer 1993; 71: 419–429
   PubMed Web of Science ®Google Scholar
• Bauknecht T., Birmelin G., Kommoss F. Clinical significance of oncogenes and growth factors in ovarian carcinomas. J. Steroid. Biochem. Mol. Biol. 1990; 37: 855–862
   Google Scholar
• Bauknecht T., Kommoss F., Birmelin G., Kleist S. von, Kohler M., Pfleiderer A. Expression analysis of EGF‐R and TGFα in human ovarian carcinomas. Anticancer Res. 1991; 11: 1523–1528
   Google Scholar
• Berchuck A., Kamel A., Whitaker R., Kems B., Olt G., Kinney R., Soper J. T., Dodge R., Clark‐Pearson D. L., Marks P., McKenzie S., Yin S., Bast R. C. Overexpression of HER‐2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990; 50: 4087–4091
   PubMed Web of Science ®Google Scholar
• Berchuck A., Olt G. J., Everitt L., Soisson A. P., Bast R. C., Boyer C. M. The role of peptide growth factors in epithelial ovarian cancer. Obstet. Gynecol. 1990; 75: 255–262
   PubMed Web of Science ®Google Scholar
• Westermann A. M., Beijnen J. H., Moolenaar W. H., Rodenhuis S. Growth factors in human ovarian cancer. Cancer Treat. Rev. 1997; 23: 113–131
   PubMed Web of Science ®Google Scholar
• Niikura H., Sasano H., Sato S., Yajima A. Expression of epidermal growth factor‐related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int. J. Gynecol. Pathol. 1997; 16: 60–68
   PubMed Web of Science ®Google Scholar
• Morishige K., Kurachi H., Amemiya K., Adachi H., Inoue M., Miyake A., Tanizawa O., Sakoyama Y. Involvement of transforming growth factor α/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro. Cancer Res. 1991; 51: 5951–5955
   PubMed Web of Science ®Google Scholar
• Stromberg K., Johnson G. R., O'Connor D. M., Sorensen C. M., Gullick W. J., Kannan B. Frequent immunhistochemical detection of EGF supergene family members in ovarians carcinogenesis. Int. J. Gynecol. Pathol. 1994; 13: 342–347
   PubMed Web of Science ®Google Scholar
• Crew A. J., Langdon S. P., Miller E. P., Miller W. R. Mitogenic effects of epidermal growth factor and transforming growth factor‐alpha on EGF‐receptor positive human ovarian carcinoma cell lines. Eur. J. Cancer 1992; 28: 337–341
   Google Scholar
• Shoyab M., McDonald V. L., Bradley J. G., Todaro G. J. Amphiregulin: a bifunctional growth‐modulating glycoprotein produced by the phorbol‐12‐myristate 13‐acetate‐treated human breast adenocarcinoma cell line MCF‐7. Proc. Natl. Acad. Sci. USA 1988; 85: 6528–6532
   PubMed Web of Science ®Google Scholar
• Zhou L., Leung B. S. Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors alpha and beta 1. Blochim. Biophys. Acta 1992; 1180: 130–136
   Google Scholar
• Morishige K., Kurachi H., Amemiya K., Fujita Y., Yamamoto T., Miyake A., Tanizawa O. Evidence for the involvement of transforming growth factor α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res. 1991; 51: 5322–5328
   PubMed Web of Science ®Google Scholar
• Kurachi H., Morishige K., Amemiya K., Adachi H., Hirota K., Miyake A., Tanizawa O. Importance of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo. Cancer Res. 1991; 51: 5956–5959
   Google Scholar
• Kurachi H., Morishige K., Adachi H., Adachi K., Tasaka K., Sawada M., Miyake A. Implantation and growth of epidermal growth factor (EGF) receptor expressing human ovarian xenografts in nude mice is dependent on EGF. Cancer 1994; 74: 2984–2990
   Google Scholar
• Gordon A. W., Pegues J. C., Johnson G. R., Kannan B., Auersperg N., Stromberg K. mRNA phenotyping of the major ligands and receptors of the EGF supergene family in human ovarian epithelial cells. Cancer Lett. 1995; 89: 63–71
   Google Scholar
• Owens O. J., Stewart C., Leake R E. Growth factors in ovarian cancer. Br. J. Cancer 1991; 64: 1177–1181
   Google Scholar
• Marth C., Lang T., Cronauer M. V., Doppler W., Zeimet A. G., Bachmair F., Ullrich A., Daxenbichler G. Epidermal growth factor reduces HER‐2 protein level in human ovarian carcinoma cells. Int. J. Cancer 1992; 52: 311–316
   Google Scholar
• Kacinski B. M., Mayer A. G., King B. L., Carter D., Chambers S. K. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol. Oncol. 1992; 44: 245–253
   PubMedGoogle Scholar
• Tamura M., Sasano H., Suzuki T., Fukaya T., Funayama Y., Takayama K., Takaya R., Yajima A. Expression of epidermal growth factors and epidermal growth factor receptor in normal cycling human ovaries. Hum. Reprod. 1995; 10: 1891–1896
   PubMed Web of Science ®Google Scholar
• Kommoss F., Bauknecht T., Birmelin G., Kohler M., Tesch H., Pfleiderer A. Oncogene and growth factor expression in ovarian cancer. Acta Obstet. Gynecol. Scand. 1992; 155: 19–24
   Google Scholar
• Kommoss F., Wintzer H. O., Kleist S. von, Kohler M., Walker R., Langdon B., Tran K. van, Pfleiderer A. In situ distribution of transforming growth factor alpha in normal tissues and malignant tumours of the ovary. J. Pathol. 1992; 162: 223–228
   Google Scholar
• Kohler M., Bauknecht T., Grimm M., Birmelin G., Kommoss F., Wagner E. Epidermal growth factor receptor and transforming growth factor α expression in human ovarian carcinomas. Eur. J. Cancer 1992; 28A: 1432–1437
   Google Scholar
• Owens O. J., Leake R. E. Growth factor content in normal and benign ovarian tumours. Eur. J. Obstet. Gynecol. Reprod. Biol. 1992; 47: 223–228
   Google Scholar
• Bartlett J. M., Langdon S. P., Simpson B. J., Stewart M., Katsaros D., Sismondi P., Love S., Scott W. N., Williams A. R., Lessells A. M., Macleod K. G., Smyth J. F., Miller W. R. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 1996; 73: 301–306
   PubMed Web of Science ®Google Scholar
• Yeh J., Yen Y. C. Transforming growth factor‐alpha and human cancer. Biomed. Pharmacother. 1989; 43: 651–659
   PubMedGoogle Scholar
• Lewis G. D., Lofgren J. A., McMurtrey A. E., Nuijens A., Fendly B. M., Bauer K. D., Sliwkowski M. X. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res. 1996; 56: 1457–1465
   PubMed Web of Science ®Google Scholar
• Simpson B. J., Langdon S. P., Rabiasz G. J., Macleod K. G., Hirst G. L., Bartlett J. M., Crew A. J., Hawkins R. A., Macineira‐Perez P. P., Smyth J. F., Miller W. R. Estrogen regulation of transforming growth factor‐alpha in ovarian cancer. J. Steroid. Biochem. Mol. Biol. 1998; 64: 137–145
   Google Scholar
• Ridderheim M., Stendahl U., Backstrom T. Progesterone and estradiol stimulate release of epidermal growth factor/transforming growth factor alpha by ovarian tumours in vitro. Anticancer Res. 1994; 14: 2763–2768
   Google Scholar
• Wimalasena J., Dostal R., McEhan D. Gonadotropins, estradiol, and growth factors regulate epithelial ovarian cancer cell growth. Gynecol. Oncol. 1992; 46: 345–350
   Google Scholar
• Wimalasena J., McEhan D., Dostal R., Foster J. S., Cameron M., Smith M. Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol. Res. 1993; 5: 325–337
   Google Scholar
• Ridderheim M., Cajander S., Tavelin B., Stendahl U., Bachstrom T. EGF/TGF‐alpha and progesterone in urine of ovarian cancer patients. Anticancer Res. 1994; 14: 2119–2123
   PubMed Web of Science ®Google Scholar
• Feldkamper M., Enderle‐Schmitt U., Hackenberg R., Schulz K. D. Urinary excretion of growth factors in patients with ovarian cancer. Eur. J. Cancer 1994; 30A: 1851–1858
   PubMedGoogle Scholar
• Kurachi H., Adachi H., Morishige K., Adachi K., Takeda T., Homma H., Yamamoto T., Miyake A. Transforming growth factor‐alpha promotes tumor markers secretion from human ovarian cancers in vitro. Cancer 1996; 78: 1049–1054
   Google Scholar
• Brader K. R., Wolf J. K., Chakrabarty S., Price J. E. Epidermal growth factor receptor antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncol. Rep. 1998; 5: 1269–1274
   PubMed Web of Science ®Google Scholar
• Rodriguez G. C., Berchuck A., Whitaker R. S., Schlossman D., Clarke‐Pearson D. L., Bast R. C. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am. J. Obstet. Gynecol. 1991; 164: 745–750
   PubMedGoogle Scholar
• Ottensmeier C., Swanson L., Strobel T., Druker B., Niloff J., Cannistra S. A. Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br. J. Cancer 1996; 74: 446–452
   Google Scholar
• Lang T., Daxenbichler G., Merth C. Effects of cytostatic agents on the expression of epidermal growth factor receptor in ovarian cancer cells. Anticancer Res. 1994; 14: 1871–1874
   PubMedGoogle Scholar
• Christen R. D., Horn D. K., Porter D. C., Andrews P. A., MacLeod C. L., Hafstrom L., Howell S. B. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest. 1990; 86: 1632–1640
   Google Scholar
• Kohler M., Janz I., Wintzer H. O., Wagner E., Bauknecht T. The expression of EGF receptors, EGF‐like factors and c‐myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res. 1989; 9: 1537–1547
   PubMed Web of Science ®Google Scholar
• Bems E. M., Klijn J. G., Henzen‐Logmans S. C., Rodenburg C. J., van der Burg M. E., Foekens J. A. Receptors for hormones and growth factors and (onco)‐gene amplification in human ovarian cancer. Int. J. Cancer 1992; 52: 218–224
   Google Scholar
• Henzen‐Logmans S. C., van der Burg M. E., Foekens J. A., Bems P. M., Brussee R., Fieret J. H., Klijn J. G., Chadha S., Rodenburg C. J. Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study. J. Cancer Res. Clin. Oncol. 1992; 118: 303–307
   Google Scholar
• Scambia G., Benedetti‐Panici P., Battaglia F., Ferrandin G., Baiocchi G., Greggi S., Vincenzo R. De, Mancuso S. Significance of epidermal growth factor receptor in advanced ovarian cancer. J. Clin. Oncol. 1992; 10: 529–535
   Google Scholar
• Stewart C. J., Owens O. J., Richmond J. A., McNicol A. M. Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int. J. Gynecol. Pathol. 1992; 11: 266–272
   Google Scholar
• Van der Burg M. E., Henzen‐Logmans S. C., Foekens J. A., Berns E. M., Rodenburg C. J., Putten W. Van L., Klijn J. G. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur. J. Cancer 1993; 29A: 1951–1957
   Google Scholar
• Simpson B. J., Phillips H. A., Lessells A. M., Lamgdon S. P., Miller W. R. C‐erbB growth‐factor‐receptor proteins in ovarian tumours. Int. J. Cancer 1995; 64: 202–206
   PubMed Web of Science ®Google Scholar
• Minguillon C., Schönborn I., Reles A., Bartel U., Lichtenegger W. EGF‐R and PCNA expression in ovarian carcinomas ‐ correlation with classic prognostic factors. Gen. Diagn. Pathol. 1996; 141: 197–201
   Google Scholar
• Janinis J., Nakopoulou L., Panagos G., Davaris P. Immunohistochemical expression of EGF‐R in malignant surface epithelial ovarian neoplasms (SEON). Eur. J. Gynaecol. Oncol. 1994; 15: 19–23
   Google Scholar
• Meden H., Marx D., Raab T., Kron M., Schauer A., Kuhn W. EGF‐R and overexpression of the oncogene c‐erbB‐2 in ovarian cancer: immunohistochemical findings and prognostic value. J. Obstet. Gynecol. 1995; 21: 167–178
   Google Scholar
• Brandt B., Vogt U., Schlotter C. M., Jakisch C., Werkmeister R., Thomas M., Eiff M. von, Bosse U., Assmann G., Zanker K. S. Prognostic relevance of abberations in the c‐erbB oncogenes from breast, ovarian, oral and lung cancers: double‐differential polymerase chain reaction (ddPCR) for clinical diagnosis. Gene 1995; 159: 35–42
   Google Scholar
• Scoccia B., Lee Y. M., Niederberger C., Ilekis J V. Expression of the ErbB family of receptors in ovarian cancer. J. Soc. Gynecol. Investig. 1998; 5: 161–165
   Google Scholar
• Ilekis J. V., Connor J. P., Prins G. S., Ferrer K., Niederberger C., Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol. Oncol. 1997; 66: 250–254
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A., Press M. F. Studies of the HER‐2/neu proto‐oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Meden H., Kuhn W. Overexpression of the oncogene c‐erbB‐2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur. J. Obstet. Gynecol. Reprod. Biol. 1997; 71: 173–179
   PubMed Web of Science ®Google Scholar
• Rubin S. C., Finstad C. L., Wong G. Y., Almadrones L., Plante M., Lloyd K. O. Prognostic significance of HER‐2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am. J. Obstet. Gynecol. 1993; 168: 162–169
   PubMed Web of Science ®Google Scholar
• Rubin S. C., Finstad C. L., Federici M. G., Scheiner L., Lloyd K. O., Hoskins W. J. Prevalence and significance of HER‐2/neu expression in early epithelial ovarian cancer. Cancer 1994; 73: 1456–1459
   PubMed Web of Science ®Google Scholar
• Haldane J. S., Hird V., Hughes C. M., Gullick W. J. C‐erbB‐2 oncogene expression in ovarian cancer. J. Pathol. 1990; 162: 231–237
   PubMed Web of Science ®Google Scholar
• Singleton T. P., Perrone T., Oakley G., Niehans G. A., Carson L., Cha S. S., Strickler J. G. Activation of c‐erbB‐2 and prognosis in ovarian carcinoma. Cancer 1994; 73: 1460–1466
   PubMed Web of Science ®Google Scholar
• Felip E., Campo J. del M., Rubio D., Vidal M. T., Colomer R., Bermejo B. Overexpression of c‐erbB‐2 in epithelial ovarian cancer. Cancer 1995; 75: 2147–2152
   PubMed Web of Science ®Google Scholar
• Seidman J. D., Frisman D. M., Norris H. J. Expression of the HER‐2/neu proto‐oncogene in serous ovarian neoplasms. Cancer 1992; 70: 2857–2860
   PubMed Web of Science ®Google Scholar
• Harlozinska A., Bar J. K., Sobanska E., Goluda M. Epidermal growth factor receptor and c‐erbB‐2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. Tumor Biol. 1998; 19: 364–373
   PubMedGoogle Scholar
• Baselga J., Mendelsohn J. Type I receptor tyrosine kinase as target for therapy in breast cancer. J. Mam. Gland Biol. Neopl. 1997; 2: 165–174
   PubMed Web of Science ®Google Scholar
• O'Rourke D. M., Greene M. I. Immunologic approaches to inhibiting cell‐surface‐residing oncoproteins in human tumors. Immunol. Res. 1998; 17: 179–189
   PubMed Web of Science ®Google Scholar
• Baselga J., Tripathy J., Mendelsohn J., Baughman S., Benz C. C., Dantis L., Sklarin N. T., Seidman A. D., Hudis C. A., Moore J., Rosen P. P., Twaddell T., Henderson I. C., Norton L. Phase II study of weekly intravenous recombinant humanized anti‐p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J. Clin. Oncol. 1996; 14: 737–744
   PubMed Web of Science ®Google Scholar
• Petit A. M., Rak J., Hung M‐C., Rockwell P., Goldstein N., Fendly B., Kerbel R. S. Neutralizing antibodies against epidermal growth factor and ErbB‐2/neu receptor tyrosine kinases down‐regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Am. J. Pathol. 1997; 151: 1523–1530
   PubMed Web of Science ®Google Scholar
• Massimo A. Di M., Loreto M. Di, Pacilli A., Raucci A., D'Alati L., Mele A., Bolognesi A., Polito L., Stirpe F., Santis R. De. Immunoconjugates made of an anti‐EGF receptor monoclonal antibody and type 1 ribosome‐inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata. Br. J. Cancer 1997; 75: 822–828
   Google Scholar
• McNeil C. Herceptin raises its sights beyond advanced breast cancer. J. Natl. Cancer Inst. 1998; 90: 882–883
   PubMed Web of Science ®Google Scholar
• Slamon D., Leyland‐Jones B., Shak S., Paton V., Bajamonde A., Flemming T., Eiermann W., Wolter J., Baselga J., Norton L. Addition of Herceptin (humanized anti‐HER2 antibody) to first line chemotherapy for HER2 over‐expressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. ASCO Proc. 1998; 17: 98a
   Google Scholar
• Cobleigh M. A., Vogel C. L., Tripathy D., Robert N. J., Scholl S., Fehrenbacher L., Paton V., Shak S., Lieberman G., Slamon D. Efficacy and safety of Herceptin (humanized anti‐HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. ASCO Proc. 1998; 17: 97a
   Google Scholar
• Ye D., Mendelsohn J., Fan Z. Augmentation of a humanized anli‐HER2 mAb 4D5 induced growth inhibition by a human‐mouse chimeric anti‐EGF receptor mAb C225. Oncogene 1999; 18: 731–8
   PubMed Web of Science ®Google Scholar
• Baselga J., Norton L., Masui H., Pandiclla A., Coplan K., Miller W. H., Jr., Mendelsohn J. Antitumor effects of doxorubicin in combination with anti‐epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 1998; 85: 1327–1333
   Google Scholar
• Baselga J., Norton L., Albanell J., Kim Y. M., Mendelsohn J. Recombinant humanized anti‐HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998; 58: 2825–2831
   PubMed Web of Science ®Google Scholar
• Lofts F. J., Hurst H. C., Sternberg M. J.E., Gullick W. J. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 1993; 8: 2813–2820
   PubMed Web of Science ®Google Scholar
• Fleisher M. Prognostic markers other than hormone receptors in breast cancer. J. Clin. Ligand Assay 1998; 21: 41–46
   Google Scholar
• Brandt‐Rauf P. W. The c‐erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutation Res. 1995; 333: 203–208
   PubMed Web of Science ®Google Scholar
• Mehta R. R., McDermott J. H., Hicken T. J., Marler K. C., Patel M. K., Wild L. D., Gupta T. das K. Plasma c‐erbB‐2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J. Clin. Oncol. 1998; 16: 2409–2416
   PubMed Web of Science ®Google Scholar
• Baron A. T., Lafky J. M., Boardman C. H., Balasubramaniam S., Suman V. J., Podratz K. C., Maihle N. J. Serum sErbB1 and epidermal growth factor levels as tumor markers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 129–37
   Google Scholar
• Fominaya J., Uherek C., Wels W. A chimeric fusion protein containing transforming growth factor‐alpha mediates gene transfer via binding to the EGF receptor. Gene Ther. 1998; 5: 521–530
   PubMed Web of Science ®Google Scholar
• Yang D., Kuan C‐T., Payne J. Recombinant heregulin‐pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Clin. Cancer Res. 1998; 4: 993–1004
   PubMed Web of Science ®Google Scholar
• Fry D. W., Nelson J. M., Slintak V., Keller P. R., Rewcastle G. W., Denny W. A., Zhou H., Bridges A. J. Biochemical and antiproliferative properties of 4‐[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem. Pharmacol. 1997; 54: 877–887
   PubMed Web of Science ®Google Scholar
• Bos M., Mendelsohn J., Kim Y‐M., Albanell J., Fry D. W., Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number‐dependent manner. Clin. Cancer Res. 1997; 3: 2099–2106
   PubMed Web of Science ®Google Scholar
• Lydon N. B., Mett H., Mueller M., Becker M., Cozens R. M., Stover D., Daniels D., Traxler P., Buchdunger E. A potent protein‐tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor‐expressing tumor cells in vitro and in vivo. Int. J. Cancer 1998; 76: 154–163
   Google Scholar
• Moroni M. C., Willingham M. C., Beguinot L. EGF‐R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J. Biol. Chem. 1992; 267: 2714–2722
   PubMed Web of Science ®Google Scholar
• Rubenstein M., Mirochnik Y., Ray V., Guinam P. Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors. Med. Oncol. 1997; 14: 131–136
   Google Scholar
• Dixit M., Yang J‐L., Poirier M. C., Price J. O., Andrews P. A., Arteaga C. L. Abrogation of cisplatin‐induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J. Natl. Cancer Inst. 1997; 89: 365–373
   PubMed Web of Science ®Google Scholar
• Yamazaki H., Kijima H., Ohnishi Y., Abe Y., Oshika Y., Tsuchida T., Tokunaga T., Tsugu A., Ueyama Y., Tamaoki N., Nakamura M. Inhibition of tumor growth by ribozyme‐mediated suppression of aberrant epidermal growth factor receptor gene expression. J. Natl. Cancer Inst. 1998; 90: 581–587
   PubMed Web of Science ®Google Scholar
• Moscatello D. K., Ramirez G., Wong A. J. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 1997; 57: 1419–1424
   PubMed Web of Science ®Google Scholar
• Yang D., Wang S. Small molecule antagonsists targeting growth factors/receptors. Curr. Pharm. Des. 1997; 3: 335–354
   Google Scholar
• Travis J. Novel anticancer agents move closer to reality. Science 1993; 260: 1877–1878
   PubMed Web of Science ®Google Scholar
• Kelloff G. J., Lubet R. A., Fay J. R., Steele V. E., Boone C. W., Crowell J. A., Sigman C. C. Famesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev. 1997; 6: 267–282
   PubMed Web of Science ®Google Scholar
• Gibbs J. B., Oliff A. The potential of famesyltransferase inhibitors as cancer chemotherapeutics. Ann. Rev. Pharmacol. Toxicol. 1997; 37: 143–166
   PubMed Web of Science ®Google Scholar
• Mangues R., Corral T., Kohl N. E., Symmans W. F., Lu S., Malumbres M., Gibb J. B., Oliff A., Pellicer A. Antitumor effect of a famesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N‐ras in transgenic mice. Cancer Res. 1998; 58: 1253–1259
   PubMed Web of Science ®Google Scholar
• Li N., Batzer A., Daly R., Yajnik V., Skolnik E., Chardin P., Bar‐Sagi D., Margolis B., Schlessinger J. Guanine‐nucleotide‐releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signaling. Nature 1993; 363: 15–16
   Google Scholar